Markets:

Overview

News

Currencies

International

Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

82.24 +0.39 (+0.48%)

Streaming Delayed Price Updated: 12:10 PM EDT, Jun 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

2 Cash-Producing Stocks to Research Further and 1 Facing Challenges

June 09, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

Ani (ANIP) Q1 2026 Earnings Call Transcript ↗

June 01, 2026

Ani (ANIP) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

2 Growth Stocks with Explosive Upside and 1 We Avoid

May 29, 2026

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...

Via StockStory

ANI Pharmaceuticals (NASDAQ:ANIP) Crushes Q1 Estimates, Raises Full-Year Guidance ↗

May 08, 2026

Via Chartmill

ANI Pharmaceuticals Inc (NASDAQ:ANIP) Surges 12% After Q4 Earnings Beat ↗

February 27, 2026

Via Chartmill

Q1 Earnings Outperformers: ANI Pharmaceuticals (NASDAQ:ANIP) And The Rest Of The Pharmaceuticals Stocks

May 18, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence Intellectual Property

2 Profitable Stocks with Competitive Advantages and 1 Facing Headwinds

May 14, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Via StockStory

Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million ↗

May 11, 2026

ANI Pharmaceuticals develops and manufactures branded and generic drugs for diverse North American healthcare markets.

Via The Motley Fool

ANI Pharmaceuticals Q1 Earnings Call Highlights ↗

May 08, 2026

ANI Pharmaceuticals (NASDAQ:ANIP) reported first-quarter 2026 results that management said show continued progress in its effort to “accelerat[e] our transformation into a leading rare disease...

Via MarketBeat

Topics Earnings Intellectual Property

ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Impressive Q1 CY2026, Stock Soars

May 08, 2026

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q1 CY2026, with sales up 20.5% year on year to $...

Via StockStory

ANI Pharmaceuticals (ANIP) Q1 Earnings: What To Expect

May 06, 2026

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Friday before market open. Here’s what you need to know. A...

Via StockStory

Topics Artificial Intelligence

Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks

April 26, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Winners And Losers Of Q4: Elanco (NYSE:ELAN) Vs The Rest Of The Pharmaceuticals Stocks

April 22, 2026

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Elanco (NYSE:ELAN) and its peers. The pharmaceuti...

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Cash-Producing Stock with Promising Prospects and 2 Facing Challenges

April 14, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Via StockStory

Topics Economy

1 Small-Cap Stock for Long-Term Investors and 2 We Turn Down

April 13, 2026

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...

Via StockStory

Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know

April 07, 2026

What Happened? A number of stocks jumped in the afternoon session after the government announced a surprise increase in payment rates for Medicare Advantage ...

Via StockStory

3 Russell 2000 Stocks We Steer Clear Of

March 30, 2026

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...

Via StockStory

ANI Pharma Insider Sells 4,772 Shares as Revenue Hits $883 Million in 2025 ↗

March 27, 2026

Specializing in branded and generic pharmaceuticals, this sector player reported a notable insider sale amid a stable transaction pattern.

Via The Motley Fool

Topics Regulatory Compliance

3 Reasons ANIP is Risky and 1 Stock to Buy Instead

March 24, 2026

What a brutal six months it’s been for ANI Pharmaceuticals. The stock has dropped 22.2% and now trades at $73.90, rattling many shareholders. This may have i...

Via StockStory

Topics Supply Chain

2 of Wall Street’s Favorite Stocks Worth Your Attention and 1 We Question

March 20, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Via StockStory

Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL)

March 11, 2026

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Profitable Stocks That Concern Us

March 11, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Via StockStory

Q4 Earnings Roundup: Amneal (NASDAQ:AMRX) And The Rest Of The Generic Pharmaceuticals Segment

March 10, 2026

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Generic Pharmaceuticals Q4 Earnings: ANI Pharmaceuticals (NASDAQ:ANIP) Simply the Best

March 04, 2026

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including ANI Pharmaceutica...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know

February 27, 2026

A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures.

Via StockStory

Topics Economy Stocks

ANI Pharma (ANIP) Q4 2025 Earnings Call Transcript ↗

February 27, 2026

ANI Pharma (ANIP) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

ANI Pharmaceuticals (NASDAQ:ANIP) Beats Expectations in Strong Q4 CY2025, Stock Jumps 12.4%

February 27, 2026

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q4 CY2025, with sales up 29.6% year on year to $247.1 million. The company’s full-year...

Via StockStory

1 Safe-and-Steady Stock Worth Your Attention and 2 That Underwhelm

February 09, 2026

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

3 Small-Cap Stocks That Fall Short

February 03, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

1 Cash-Producing Stock on Our Buy List and 2 We Brush Off

January 25, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

Topics Supply Chain

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.